托珠单抗与沙利鲁单抗在重症新冠患者中的疗效
本研究为国际、多因素、适应性平台试验(REMAP-CAP),纳入ICU启动器官支持24小时内的成人新冠患者,随机接受托珠单抗8 mg/kg、沙利鲁单抗400 mg或标准治疗。主要终点为21天内无呼吸和心血管器官支持天数(院内死亡赋值为-1)。托珠单抗组353例、沙利鲁单抗组48例、对照组402例;中位无器官支持天数分别为10天、11天和0天。校正累积比值比托珠单抗1.64(95%可信区间1.25至2.14)、沙利鲁单抗1.76(95%可信区间1.17至2.91),优于对照的后验概率分别>99.9%和99.5%;汇总白介素-6受体拮抗剂组90天生存改善,风险比1.61(95%可信区间1.25至2.08),后验概率>99.9%。
要点
- 在ICU启动器官支持24小时内的成人新冠患者中,托珠单抗8 mg/kg与沙利鲁单抗400 mg均达到预设疗效标准。
- 中位无器官支持天数:托珠单抗组10天(四分位距-1至16),沙利鲁单抗组11天(四分位距0至16),对照组0天(四分位距-1至15)。
- 校正累积比值比:托珠单抗1.64(95%可信区间1.25至2.14),沙利鲁单抗1.76(95%可信区间1.17至2.91),优于对照的后验概率分别>99.9%和99.5%。
- 汇总白介素-6受体拮抗剂组90天生存改善,与对照相比风险比1.61(95%可信区间1.25至2.08),后验概率>99.9%。
- 所有次要分析均支持白介素-6受体拮抗剂的疗效。
适用人群与场景
- 成人新冠患者,在ICU启动器官支持后24小时内随机分组。
处置流程与药物剂量
- 托珠单抗8 mg/kg体重,静脉给药(原文未写明给药途径,仅写剂量),单次给药。
- 沙利鲁单抗400 mg,静脉给药(原文未写明给药途径,仅写剂量),单次给药。
- 对照组接受标准治疗。
研究设计与关键结果
- 研究类型:国际、多因素、适应性平台试验(REMAP-CAP),采用贝叶斯统计模型,预设优效、有效、等效或无效标准;比值比大于1代表生存改善、无器官支持天数增多或两者兼有。
- 样本量:托珠单抗组353例,沙利鲁单抗组48例,对照组402例。
- 主要终点(21天内无呼吸和心血管器官支持天数,院内死亡赋值为-1):中位数托珠单抗组10天(四分位距-1至16),沙利鲁单抗组11天(四分位距0至16),对照组0天(四分位距-1至15)。
- 校正累积比值比:托珠单抗1.64(95%可信区间1.25至2.14),沙利鲁单抗1.76(95%可信区间1.17至2.91);优于对照的后验概率分别>99.9%和99.5%。
- 90天生存:汇总白介素-6受体拮抗剂组与对照组比较,风险比1.61(95%可信区间1.25至2.08),后验概率>99.9%。
- 所有次要分析均支持白介素-6受体拮抗剂的疗效。
证据类型、等级与局限
- 证据类型:国际、多因素、适应性平台随机试验(REMAP-CAP)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU内启动器官支持24小时内的成人新冠患者,作者结论认为托珠单抗和沙利鲁单抗治疗改善了结局,包括生存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.
METHODS: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and cardiovascular organ support-free days, on an ordinal scale combining in-hospital death (assigned a value of -1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence, or futility. An odds ratio greater than 1 represented improved survival, more organ support-free days, or both.
RESULTS: Both tocilizumab and sarilumab met the predefined criteria for efficacy. At that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control. The median number of organ support-free days was 10 (interquartile range, -1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sarilumab group, and 0 (interquartile range, -1 to 15) in the control group. The median adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control, yielding posterior probabilities of superiority to control of more than 99.9% and of 99.5%, respectively. An analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a hazard ratio for the comparison with the control group of 1.61 (95% credible interval, 1.25 to 2.08) and a posterior probability of superiority of more than 99.9%. All secondary analyses supported efficacy of these interleukin-6 receptor antagonists.
CONCLUSIONS: In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.).
参考来源
- Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021. PMID: 33631065. doi:10.1056/NEJMoa2100433
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。